HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
April 11, 2023 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated...
Intended Retirement of Independent Non-executive Director
April 11, 2023 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr...
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
April 04, 2023 05:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the...
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023 20:00 ET
|
HUTCHMED (China) Limited
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib...
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023 09:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its...
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
March 12, 2023 20:07 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it...
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
February 28, 2023 03:30 ET
|
HUTCHMED (China) Limited
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full...
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
February 27, 2023 05:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed...
HUTCHMED to Announce 2022 Final Results
January 31, 2023 03:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the...
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023 03:00 ET
|
HUTCHMED (China) Limited
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing...